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Adaptive immune responses to 
booster vaccination against yellow 
fever virus are much reduced 
compared to those after primary 
vaccination
Michael Kongsgaard1, Maria R. Bassi1, Michael Rasmussen1, Karsten Skjødt2, Søren Thybo3, 
Mette Gabriel4, Morten Bagge Hansen5, Jan Pravsgaard Christensen  1, Allan Randrup 
Thomsen  1, Soren Buus1 & Anette Stryhn1
Outbreaks of Yellow Fever occur regularly in endemic areas of Africa and South America frequently 
leading to mass vaccination campaigns straining the availability of the attenuated Yellow Fever 
vaccine, YF-17D. The WHO has recently decided to discontinue regular booster-vaccinations since a 
single vaccination is deemed to confer life-long immune protection. Here, we have examined humoral 
(neutralizing antibody) and cellular (CD8 and CD4 T cell) immune responses in primary and booster 
vaccinees (the latter spanning 8 to 36 years after primary vaccination). After primary vaccination, we 
observed strong cellular immune responses with T cell activation peaking ≈2 weeks and subsiding to 
background levels ≈ 4 weeks post-vaccination. The number of antigen-specific CD8+ T cells declined 
over the following years. In >90% of vaccinees, in vitro expandable T cells could still be detected 
>10 years post-vaccination. Although most vaccinees responded to a booster vaccination, both the 
humoral and cellular immune responses observed following booster vaccination were strikingly reduced 
compared to primary responses. This suggests that pre-existing immunity efficiently controls booster 
inoculums of YF-17D. In a situation with epidemic outbreaks, one could argue that a more efficient use 
of a limited supply of the vaccine would be to focus on primary vaccinations.
The Yellow Fever virus (YFV) causes acute haemorrhagic fever, which in ≈15% of cases can progress to a more 
severe, and potentially lethal, stage of the disease1, 2. It is a considerable health burden; in the early 1990’es it was 
estimated that the worldwide annual incidence was 200,000 severe cases and 30,000 deaths; numbers that largely 
still stands3. The virus infects humans that live in, or travel to, parts of tropical and subtropical Africa and South 
America, where the infection is endemic due to the concurrent existence of transmitting mosquitos and a virus 
reservoir. The vectors are widespread4, and the reservoirs can be found both in humans and non-human primates; 
conditions that make the disease difficult to control, and virtually impossible to eradicate. Indeed, Yellow Fever 
re-emerges regularly in endemic areas. The most recent major epidemic outbreak started in Angola in December 
2015. As of June 2016, 3,137 suspected cases and 345 deaths have been reported. Further compounding the need 
for containment and control, this virus is a potential threat to human health in all parts of the world where the 
transmitting mosquito vectors and the conditions for establishing a reservoir exist e.g. in South-East Asia1. In 
this context, it is worth noting that at least eleven cases of Yellow Fever infected persons traveling from Angola to 
China have been discovered since December 20155, 6.
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In the absence of specific treatment, prevention through vaccination is one of the most effective strategies to 
reduce the risk of disease and to lower morbidity. The current vaccines against YFV are based on a live attenuated 
virus strain, YF-17D, which was isolated by Max Theiler and co-workers in 19377 (he was awarded the Nobel prize 
in Medicine in 1951 for this discovery8). Briefly, the pathogenic wild-type Asibi strain was empirically attenuated 
through multiple adaptations, which involved successive serial passages in Rhesus monkeys, whole mouse embry-
onic tissue, whole chicken embryonic tissue, and finally denervated chicken embryonic tissue. Over the past 70 
years, more than 540 million doses have been administered to humans who live in, or travel to, endemic areas and 
therefore are at risk of being infected with Yellow Fever virus9. The YF-17D vaccine has earned a reputation as one 
of the most successful vaccines ever developed both in terms of efficacy and safety10. This has generated interest 
in exploring YF-17D as a backbone for chimeric vaccines against other pathogens11, 12. It has also generated con-
siderable interest in understanding the nature of the immune responses as well as the mechanisms of protection 
induced by YF-17D vaccination.
Due to its safety and its nature as a live vaccine, YF-17D vaccination offers a unique model system to study 
human immune responses during an acute viral infection. In general, antibodies have been considered the dom-
inant effector mechanism responsible for life-long, vaccine-induced immune protection13–15. It is now known 
that many different innate16–19 and cellular16, 20–26 immune mechanisms, including potent CD4+ and CD8+ T 
cells responses, contribute to the establishment of long-term immune protection. Here, we recruited 240 healthy 
volunteers, who were YF-17D vaccinated for travel purposes; 210 were primary and 30 were secondary/tertiary 
vaccinated. In a prospective, longitudinal cohort study design, we obtained blood donations before and after 
vaccination. We used these samples to examine and compare the magnitude, quality and dynamics of humoral 
and cellular immune responses following primary and secondary YFV immunization. In many cases, we used 
peptide-HLA tetramers to identify and monitor specific T cell responses. Following primary vaccination with the 
live attenuated virus, we demonstrated a brisk and strong response involving both the humoral and cellular arms 
of the immune system. Revaccination given 8–36 years after primary vaccination induced much lower responses 
suggesting that the late memory responses could reduce and possibly control the Yellow Fever virus.
Materials and Methods
Approvals, informed consent, animal experiments and accordance. The Danish National 
Committee on Health Research Ethics approved this study (protocol #H-1-2009-095). The collection of data 
and cells was approved by The Danish Data Protection Agency (permission #2008-41-2732). All volunteers gave 
written informed consent prior to participation. Mice were housed in an AAALAC accredited facility in accord-
ance with good animal practice as defined by FELASA. All experiments were performed in accordance with 
national Danish guidelines including those of the National Animal Ethics Committee (The Animal Experiments 
Inspectorate).
Donors and Yellow Fever vaccination. Healthy volunteers, who for traveling purposes were about to 
be vaccinated against YFV, were recruited at two local vaccination clinics. According to interviews of previous 
YFV vaccination history, and by examination of each individual’s International Card of Vaccination, these volun-
teers were assigned as being naïve or previously YFV vaccinated individuals, who were about to receive primary 
or booster vaccination, respectively. After informed consent had been obtained, the attenuated YFV vaccine, 
YF-17D-204 (Sanofi Pasteur; marketed as Stamaril in Europe, and as YF-VAX in the USA) was administered 
intramuscularly. About 42% of the volunteers only received an YFV vaccination, whereas the remaining 58% 
received additional vaccines. These additional vaccines were typically killed, inactivated or subunit vaccines; in 
no case was the YFV vaccine co-administered with any other live attenuated vaccines.
Blood samples and PBMC preparation. Blood samples were obtained before vaccination and at various 
time points after vaccination (typically day 10–20, range 9 to 41). In some cases, memory samples were collected 
approximately 2 years after primary vaccination. PBMC from the heparinized blood samples were obtained by 
Ficoll-Paque density gradient centrifugation and analysed directly, or cryopreserved in 10% DMSO and 90% FCS 
for later analysis. Sera from the donors were frozen for serological analysis.
High-resolution HLA-typing. Chromosomal DNA was isolated from the PBMC’s and used to perform 
high-resolution (i.e. 4 digit) HLA-typing (Genome Diagnostics, Utrecht, The Netherlands). All loci encoding 
classical (i.e. polymorphic, peptide presenting) HLA molecules were identified. This included three class I Ioci, 
HLA-A, -B, -C and six class II loci, HLA-DRB1, -DRB3,4,5, -DQA1, -DQB1, -DPA1 and -DPB1.
Activation marker analysis. Initially, we analysed the complete CD8+ T cell activation phenotype, CD38+, 
HLA-DR+, Ki-67+ and Bcl-2low, suggested by Miller et al.26. However, after having analysed the first approximately 
190 donor samples (Supplementary Figure S1), we came to the conclusion that we would lose very little infor-
mation in terms of the size of the activated CD8+ T cell population if we only used the two extracellular markers, 
rather than the complete activation phenotype.
Thus, PBMCs were analysed ex vivo for T cell (CD3, CD4, CD8) and the extracellular T cell activation mark-
ers, CD38, HLA-DR. Briefly, PBMCs were incubated with fluorochrome-conjugated anti-CD3, -CD4, -CD8, 
-CD38 and -HLA-DR antibodies for 30 minutes at room temperature, washed, fixed with 1% formaldehyde, and 
analysed by flow cytometry (LSR-II, BD Biosciences) using Diva software. For representative FACS plots see 
Supplementary Figure S2.
Peptides and antibodies. A systematic library of overlapping 15-mer peptides spanning the entire YF-17D 
proteome (UniProt# P03314) of 3411 amino acids was synthesized (all peptides were supplied HPLC-purified 
(minimum 80%, in most cases >95%), mass spectrometry validated and lyophilized by Schafer-N (Copenhagen, 
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Denmark)). Each peptide overlapped its neighbouring peptides with 11 amino acids. The approximately 850 pep-
tides (the synthesis of a few peptide failed) were organized into 30 pools with 28–30 peptides in each pool. The 
resulting peptide pools were used to stimulate YFV-specific T cell responses.
All monoclonal antibodies were obtained from BioLegend (San Diego, CA, USA), except for the previously 
reported anti-YF NS3 monoclonal antibody, 12-25-627, which was purified from culture supernatants.
Cell culture and peptide stimulation. PBMCs were incubated over night with a mixture of relevant pep-
tides at a concentration of 0.5 µM of each peptide in X-vivo 15 (Fisher Scientific) media supplemented with 5% 
AB Serum (Invitrogen). The cells were subsequently harvested, washed and plated at a concentration of 5 × 106/
ml supplemented with 50U/ml IL-2 for expansion. Fresh media and IL-2 were supplemented every second day 
until the cells were harvested at day 8, and IL-15 (15ng/ml) was added the last four days.
Tetramers. HLA class I tetramers were produced as previously described28. Briefly, recombinant, biotinylated 
HLA class I heavy chain, human β2-microglobulin and peptide were incubated in 50 mM tris-maleate pH 6.6 
and 0.1% Pluronic F68 for 48 h at 18 °C. The resulting monomers were tetramerized by addition of fluorochrome 
labelled Streptavidin (Streptavidin-PE or Streptavidin-APC; all from BioLegend) sequentially over 60 min at a 
1:4 molar ratio of streptavidin to monomer. Here, we have used tetramers representing 12 YFV epitopes. Three 
have previously been published: NS4B214-222 (LLWNGPMAV)-A*02:0121; NS5672-680 (RPIDDRFGL)-B*07:0229; 
NS2A4-13 (HAVPFGLVSM)-B*35:0123. Nine are novel epitopes: NS5286–295 (KSEYMTSWFY)-A*01:01; NS34-12 
(VLWDIPTPK)-A*03:01; NS324-32(IYGIFQSTF)-A*24:01; NS5476-484 (WYMWLGARY)-A*29:02; NS1116-124 
(KTWGKNLVF)-A*32:01; EnvE207–215 (RQWAQDLTL)-B*13:02; NS373-81 (SVKEDLVAY)-B*15:01; EnvE200-
209 (TESWIVDRQW)-B*44:02; NS3207-213 (TRRFLPQIL)-C*06:02. The identification of these epitopes will be 
described elsewhere.
Pellets of 106 PBMCs obtained ex vivo, or pellets from 2 ×105 cells obtained from in vitro peptide stimulated 
cell cultures, were re-suspended in a 10 µl tetramer solution at a final concentration of ≈30 nM, and incubated 
for 20 min at room temperature, followed by 30 min incubation with fluorochrome conjugated anti-CD3, -CD8, 
-CD38 and -HLA-DR antibodies. The cells were analysed by flowcytometry (Fortessa or LSR-II, BD Biosciences) 
using Diva software. Supplementary Figure S3, a NS4B214-222-A*02:01 tetramer ex vivo staining pre- and post-YF 
vaccination, illustrates the tetramer background level.
Ex-vivo Interferon-γ ELI Spot assay. As previously described, fresh or thawed PBMCs were tested 
using an Interferon-γ specific ELI Spot assay30. Briefly, 2–3 × 105 cells/well were plated in an ELI Spot plate 
(MAHAS4510, Merck Millipore, USA) and in vitro cultured for 18–24 hours in media supplemented with or 
without peptide at 0.5 µM (or, as positive control, with 1 µg/ml Staphylococcal enterotoxin B (SEB, Sigma Aldrich, 
St. Louis, USA). AP conjugate substrate kit (Bio-Rad) was used for visualization of spots. ELI spot were counted 
using a CTL ImmunoSpot series 5 UV Analyzer and ImmunoSpot 5.0.9 software (C.T.L., Shaker Heights, USA) 
was used for analysis. Wells with SPU >2 times the background wells were considered positive.
YF-17D virus preparation and quantitation. YF-17D virus (Stamaril, Sanofi Pasteur; reconstituted as 
recommended by the manufacturer) was propagated in Vero (ATCC CCL-81) cells as previously described27. In 
brief, cell monolayers were seeded 24 hours earlier and infected with at a multiplicity of infection (MOI) of 0.001/
cell in DMEM 2% FCS. Infectious supernatants were harvested when cytopathic effect was more than 60% (day 
6 p.i.), freeze-thawed and clarified of cell debris at 2000 rpm for 15 min at 4 °C. Viral stocks were stored as single 
use aliquots at −80 °C.
Infectious virus titres were determined by an Immuno Focus Assay (IFA) as previously described27. In brief, 
virus stocks were serially diluted (ten-fold) in DMEM and adsorbed for 1 h at 37 °C onto Vero (ATCC CCL-81) 
cell monolayers in twenty-four-well plates; cells were then overlaid with media containing 0.9% methyl cellulose 
and incubated at 37 °C for 3 days. Following fixation and permeabilisation, a monoclonal antibody, 12-25-627, 
directed against NS3 from YF-17D virus was used for detection of virus antigens within infected cells; the foci of 
infection (analogous to plaques) were visualized using HRP-substrate reaction and counted.
Plaque reduction neutralization test (PRNT) and titre. Appropriately diluted YF-17D (generat-
ing 70–100 pfu/well) was incubated 1 h at 37 °C with serial 2-fold dilutions of pre- or post-vaccination serum 
from primary or booster-vaccinated donors. The resulting virus-serum mixtures were added to monolayers of 
Vero cells in 24-well plates, incubated at 37 °C for 2 h, overlaid with media containing 0.9% methyl cellulose, 
and the incubation continued for another 3 d at 37 °C. After fixation (4% formaldehyde) and permeabilisation 
(0.5% Triton-X100 in Hanks media), a monoclonal mouse antibody, 12-25-6, specific for the N-terminal end 
of NS3 from the YF-17D virus was used for detection of infected cells. Foci of infection were visualized with an 
HRP-conjugated secondary antibody, and subsequently counted. The PRNT50 titre was defined as the reciprocal 
of the last serum dilution, which caused a 50% reduction in the number of plaques. All PRNT values were log 
transformed before statistical analysis.
Recombinant adenoviral vectors. A recombinant Adenovirus 5 (Ad5) vector encoding the structural 
proteins core, membrane and envelope (C, M, E) from YF-17D virus (GenBank# X03700.1) was produced 
through homologous recombination by standard methods31, 32. After purification on a caesium chloride (CsCl) 
density gradient, the viral stock was immediately frozen as single use aliquots in 10% glycerol at −80 °C, and the 
infectivity of the stock was determined using the Adeno-X Rapid Titer kit (BD Clontech). The presence of the 
inserted transgenes in the recombinant Ad5 vector was validated by sequence analysis prior to its use for vacci-
nation in mice.
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Mice. Female C57BL/6 (wt. B6) mice were obtained from Taconic Farms and housed in a pathogen – free 
facility; animals were used in experiments when 7–10 weeks old. All experiments were approved by the national 
animal ethics committee and performed in accordance to the national guidelines.
Vaccination of mice. For adenovirus vaccination, 2 × 107 pfu of recombinant Ad-5 in a volume of 30 µl was 
given subcutaneously to isofluorane-anesthetized mice in the right hind footpad. Vaccination with YF-17D virus 
at the dose of 105 pfu in 300 µl was given subcutaneously (s.c.) at the base of the tail.
Spleen cell preparation and flow cytometry. Single cell suspensions of splenocytes were obtained by 
pressing the organs through a fine steel mesh (mesh size, 70 µm), followed by centrifugation and re-suspension in 
RPMI 1640 cell culture medium. The frequencies of antigen-specific CD8+ T cells in the spleen were determined 
by intracellular cytokine staining (ICS) performed after 5 h of incubation with relevant peptides (0.1 µg/ml of 
NS3 (268-275) or E (4-12)) in the presence of monensin (3 µM) at 37 °C in 5% CO2. After incubation, the cells were 
stained with Abs for cell surface markers (peridinin chlorophyll protein-Cy5.5-CD8, APC-Cy7-CD44) and Ab 
for intracellular cytokine (APC- interferon gamma (IFN-γ)). Samples were run on an LSRII flow cytometer (BD 
biosciences) and analysed using FlowJo software (TreeStar).
Statistics. GraphPad Prism (version 5) was used for statistical analyses (unpaired and paired 
Mann-Whitney-Wilcoxon tests, unpaired and paired t-tests, Fishers exact test, and ROC analysis).
To establish a background frequency of activated CD38+HLA-DR+CD8+ T cells, we examined the data 
from blood samples taken before primary or booster vaccinations. A few donors had high frequencies of acti-
vated CD8+ T cells in the blood samples taken before vaccination; something that could be caused by on-going 
immune responses against unrecognized infections. These outliers were excluded using “Iglewicz and Hoaglin’s 
robust test for multiple outliers” (two-sided test, with the recommended setting of Z = 3.5, http://contchart.com/
outliers.aspx). Statistical analyses of samples taken from the remaining donors before vaccination were used to 
calculate the background frequencies of activated CD4+ or CD8+ T cells. As expected if outliers were caused 
by on-going immune responses, being a CD4+ outlier was significantly correlated with being a CD8+ outlier 
(two-tailed P value of 0.0014, Fishers exact test). Exclusion of outliers was only performed to establish back-
ground frequencies; it was not for used in the context of group comparisons.
Results
Recruiting volunteers. Vaccination with the live, attenuated Yellow Fever vaccine, YF-17D, is an ideal 
opportunity to investigate the dynamics and quality of human immune responses following exposure to an acute 
primary virus challenge under safe and highly controlled conditions. Volunteers, who for travel purposes were 
about to receive YF-17D vaccination, were examined. A 50 ml blood donation was obtained immediately before 
vaccination, and a 200 ml blood donation was obtained about 10–20 days after vaccination. During the two-year 
period of 2010 to 2011, a total of 294 volunteers were recruited (65% were female and 35% were male; matching 
the gender distribution of Danish blood bank donors). We obtained donations before and after vaccination from 
249 (85%) of the volunteers (the remaining 45 volunteers did not give after vaccination donations). Subsequently, 
nine volunteers were excluded (due to viral hepatitis infection, low PBMC yields, or insufficient information 
about prior immunization). Thus, paired (i.e. before and after vaccination) blood donations from 240 volunteers 
were available for these studies: 210 primary, 28 secondary and two tertiary vaccinees. The age range for the pri-
mary vaccinated group was 18–68 years, with an average age of 28.4 years; and the age range of the secondary/ter-
tiary vaccinated group was 21–61 years, with an average age of 38.5 years. For twelve of the primary vaccinees, an 
additional 200 ml blood donation was obtained approximately 2 years after vaccination. Thus, we obtained blood 
at five different time points yielding T cells at different stages of development denoted: (1) naïve T cells, which 
were sampled just before primary vaccination, (2) primary effector T cells sampled after primary vaccination, 
(3) primary memory T cells sampled about 2 years after primary vaccination, (4) late memory T cells sampled 
just before booster vaccination, which typically occurs about 10 years, or more, after primary vaccination and 
finally (5) secondary effector T cells sampled after booster vaccination. In addition, the responses of two primary 
vaccinees were followed longitudinally using multiple smaller blood donations spaced over a longer time period.
Background frequency of activated CD8+ T cells. To establish a background frequency of activated 
CD8 + T cells, we examined the frequency of CD3+, CD8+, CD38+, HLA-DR+ T cells in PBMC’s sampled 
before vaccination. Removing outliers, the background frequency of activated CD8+ T cells was found to be 
0.87% (N = 163, SD = 0.59 with a 99% confidence interval of the mean from 0.75% to 0.99% (Fig. 1A). A back-
ground activation frequency level of about 1% corresponds well to those observed in other studies26, 29, 33. About 
6% of the donors had apparent background frequency of 3% to almost 14% activated CD8+ T cells, and were 
removed as outliers. We speculate that these donors at the time of sampling might have had unnoticed infectious 
or inflammatory conditions.
Rapidly expanding and contracting primary effector CD8+ T cell responses. We adopted a longi-
tudinal study design for our study. Each donor was asked to give a blood sample approximately 14 days after vac-
cination, however, the donor themselves chose the exact time based on their convenience. These post-vaccination 
donations were obtained on average 16.4 days (SD = 3.9 days) with a range from 9 to 41 days after vaccination. 
Data obtained from 209 of 210 primary vaccinees was used to establish the kinetics of the CD8+ T cell activation 
response. The frequency of CD8+ T cells being of the CD38+, HLA-DR+ activated phenotype increased from 
day 9–10 after vaccination. Around day 14–15, it reached a plateau with an average of 5–7%, however, covering 
a wide range from 2% to 20%. This plateau lasted for about a week, and at day 22–23, the frequency of activated 
CD8+ T cells contracted and reached baseline level around day 29 (Fig. 1A). Thus, the acute virus infection caused 
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Figure 1. Activation of CD8+ T cells after primary YF-17D vaccination. PBMCs were analysed by flow 
cytometry. Activated CD8+ T cells were defined as CD38+ HLA-DR+ CD8+ CD3+ T cells (see supplementary 
Figure S1, left-hand panel). (A) Frequencies of activated CD8+ T cells before and after YFV vaccination. Pre- 
(day 0) and post-vaccination (day 9 to 43) PBMCs from 209 primary YFV vaccinated donors were analysed. 
In the left-hand panel, pre-vaccination frequencies are plotted; in the right-hand panel, the post-vaccination 
frequencies are plotted according to the day the blood sample was collected. The median for each collection day 
is indicated. Mann Whitney U test was used to determine the significance of the difference between day 0 pre-
vaccination, and the indicated day post vaccination (***p < 0.001; **p < 0.01; *p < 0.05). (B) The frequencies 
of activated and NS4B214-222/HLA-A*02:01 tetramer specific CD8+ T cells from 93 HLA-A*02:01 donors 
were analysed and plotted according to the day the blood samples were collected. (C) The previous analysis 
was extended to 11 different HLA- class I tetramer-specific CD8+ T cells from 41 primary vaccinated donors 
yielding 321 measurements of frequencies of activated and HLA class I tetramer positive CD8+ T cells, which 
are plotted according to the day the blood sample was collected. (D) PBMCs from two primary vaccinated 
donors were collected at various time points before and after primary YFV vaccination. In the left-hand panel, 
the frequencies of activated and NS4B214-222/HLA-A*02:01 tetramer positive CD8+ T cells from donor YF4967 
are plotted according to the day the blood samples were collected. In the right-hand panel, the frequencies of 
activated and NS2A4-13/HLA-B*35:01tetramer positive CD8+ T cells from donor YF7512 are plotted according 
to the day the blood samples were collected. The frequencies of tetramer+ CD8+ T cells are depicted as 
histograms with values given on the left Y-axis; whereas the frequencies of activated tetramer positive CD8+ T 
cells are depicted as a line plot with values given on the right Y-axis.
www.nature.com/scientificreports/
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by YF-17D vaccination led to expansion (Fig. 1D) and activation (Fig. 1A) of CD8+ T cells entailing a response 
cycle of about four weeks; two weeks of expansion, a plateau period of about a week with a high level of activated 
T cells in the peripheral blood, and finally a contraction period of about a week.
Next, we used peptide-HLA class I tetramers to examine the kinetics of activation of antigen-specific 
CD8+ T cells induced by primary YF-17D vaccination. Initially, we used a tetramer representing the 
HLA-A*02:01-restricted NS4B214-222 epitope identified by Akondy et al.21. This is a particularly feasible specificity 
to monitor since the HLA-A*02:01 allotype is the most frequent HLA-I allele in our donors, and the NS4B214-222 
epitope is an unusually strong immunogen in the context of HLA-A*02:01. To examine the CD8+ activation 
kinetics, we examined NS4B214-222 specific, HLA-A*02:01-restricted CD8+ T cell responses in 93 HLA-A*02:01 
donors. This immunodominant epitope was very frequently recognized (in fact, every single of the 93 primary 
YF-17D vaccinated, HLA-A*02:01-positive individuals examined responded to this epitope) and it led to very 
strong responses (up to 11% of all CD8+ T cells recognized this epitope at the peak of the primary effector 
response). Therefore, monitoring this specific response is a unique opportunity to examine the kinetics of acti-
vation and deactivation ex vivo during a primary YF-17D vaccination response (Fig. 1B). Early in the response, 
from the earliest point of observation at 9 days and until day 16 after vaccination (in some donors even up to day 
19), 90–100% of the tetramer positive CD8+ T cells were of the activated phenotype. Subsequently, a sharp decline 
in the level of activated, NS4B214-222specific, HLA-A*02:01-restricted CD8+ T cells, was observed starting at day 
19 and returning to baseline levels around day 30 (Fig. 1B).
Considering that the NS4B214-222-specific, HLA-A*02:01 response is unusually immunodominant, it could 
have unusual kinetics. We therefore extended the kinetics analysis of CD8+ primary effector T cell activation to a 
larger group of YF-17D-specific CD8+ T cell responses identified in primary vaccinated donor cohort (Fig. 1C). 
Using a panel of 11 different YF peptide-HLA-I tetramers (Supplementary Figure S4 shows representative stain-
ings of these 11 tetramers, which are also given in the tetramer section of Materials and Mathods; a detailed 
description of the identification of these epitopes will be described elsewhere), we analysed the frequency of 
activation of YF-17D-specific CD8+ T cells from 41 primary vaccinated donors. This led to the generation of 321 
data points. The early development of almost fully activated CD8+ T cells followed by a sharp decline in activa-
tion around day 20 reaching baseline around day 30 is completely superimposable with the NS4B214-222-specific, 
HLA-A*02:01 response. Thus, this activation kinetic seems to be very consistent across many different CD8+ T 
cell specificities directed against this attenuated virus.
Finally, we used tetramers to monitor both CD8+ T cell expansion and activation in two donors where the 
frequencies and activation status of two known immunodominant CD8+ T cell responses directed against the 
HLA-A*02:01-restricted NS4B214-222 epitope21 and the HLA-B*35:01-restricted NS2A4-13 epitope34, respectively, 
were examined at several consecutive time points after vaccination (Fig. 1D). The tetramer specific CD8+ T cells 
expanded rapidly and peaked about 3 weeks post vaccination. At the peak of the response, as much as 2.5% 
and 0.85% of the CD8+ T cell populations were dedicated to the recognition of these two immunodominant 
epitopes, respectively. Subsequently, the specific CD8+ T cell populations contracted rapidly over the course of 
2–3 weeks. Over the following years, the frequency slowly declined; at day 450 and 960 of the NS4B214-222-specific, 
HLA-A*02:01-restricted response, the tetramer positive cells accounted for 0.11% and 0.08%, respectively, of 
the entire peripheral CD8+ T cell population, and at day 679 of the NS2A4-13-specific, HLA-B*35:01-restricted 
response, the tetramer positive cells accounted for 0.02%. Co-staining the tetramer positive CD8+ T cells with 
CD38, allowed us to determine the activation status of the tetramer positive CD8+ T cells during these responses. 
In agreement with the activation kinetics observed in Fig. 1, all tetramer positive CD8+ T cells were activated at 
day 12, this had dropped to ≈70% at day 20, and further dropped to less than 17% at day 30, and ≈0% at day 40. 
Thus, during CD8+ T cell contraction, an increasing fraction of the dwindling population of specific CD8+ T 
cells becomes inactive (at least as defined by CD38 expression). This leaves a transitory population of specific, yet 
inactive, CD8+ T cells appearing sometime between day 12 and day 20 after vaccination and eventually account-
ing for almost all the specific CD8+ T cells observed after day 30. This is in agreement with a transition occurring 
of effector to memory T cells as described by Miller et al.26.
CD8+ T cell responses of booster-vaccinated donors are reduced compared to primary vacci-
nated donors. Our study included 30 healthy volunteers, who received booster YF-17D vaccinations; 26 
of these were sampled 12 to 22 days after vaccination, the time period of the activation plateau with consistent 
responses across all donors. The time between the primary and the booster vaccination ranged from 8 to 36 years. 
CD8+ T cells sampled from the boosted donors were examined for the expression of activation markers CD38 and 
HLA-DR before and after the booster vaccination (Fig. 2A). Although we did observe a significant, albeit modest, 
≈0.5% increase in the number of activated CD8+ T cells after booster vaccination, this increase is much smaller 
than the ≈4% increase we observed after primary vaccination (Fig. 2A). In other words, the absolute activation 
levels achieved after primary vaccination were much higher than after booster vaccination, and this difference 
was highly significant (Fig. 2A).
To further analyse the difference between primary and boosted donors at the peak of the response from 12 
to 22 days after vaccination, we selected HLA-A*02:01 positive donors from both the primary and booster vac-
cinated cohorts, and used the NS4B214-222/HLA-A*02:01 tetramer (described above) to enumerate the ex vivo 
frequency of corresponding CD8+ T cells before and after vaccination in both groups (Fig. 2B). For the pri-
mary vaccinated donors, NS4B214-222/HLA-A*02:01 tetramer-specific CD8+ T cells were absent in the naïve T 
cell samples, but were observed in all 85 primary effector samples examined (frequencies from 0.1 to 11.5% of 
CD8+ T cells). For the booster-vaccinated donors, NS4B214-222/HLA-A*02:01 tetramer-specific CD8+ T cells were 
observed in only 2 of the 12 donors examined before booster vaccination (reaching frequencies of only about 
0.3% at this late memory stage), and in 14 of the 15 donors examined after booster vaccination (reaching very low 
frequencies; only three donors had frequencies >0.1% at this secondary effector stage).
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These scarce and weak ex vivo late memory responses made us examine whether NS4B214-222/HLA-A*02:01 
tetramer-specific CD8+ T cells could be detected after in vitro culture with the NS4B214-222 peptide for 8 days 
Figure 2. CD8+ T cell responses in primary and booster vaccinated donors. PBMC’s were obtained from 
primary and booster vaccinated donors either before (day 0) or at the peak of the vaccine-induced response 
(day 12–22). (A) The frequencies of activated CD8+ T cells (i.e. CD38+ HLA-DR+ CD8+ CD3+ T cells) obtained 
before (denoted “naïve”; n = 127) and after (“primary effectors”; n = 180) primary YFV vaccination as well as 
before (“late memory”; n = 26) and after (“secondary effectors”; n = 26) booster vaccination. The median is 
indicated. Mann Whitney U test was used to determine the significance of the difference between the indicated 
groups (***p < 0.0001; **p = 0.009; *p = 0.013). (B) PBMC’s obtained from donors before (“naïve”) and after 
(“primary effectors”) primary vaccination, and from donors before (“late memory”) and after (“secondary 
effectors”) booster YFV vaccination were enumerated for NS4B214–222-specific, HLA-A*02:01-restricted CD8+ 
T cells. These analyses were performed both ex vivo (denoted “ex vivo”) and after an 8-day in vitro peptide 
stimulation and expansion culture (denoted “Expand”). Results are given as frequencies of tetramer+ CD8+ 
T cells. Mann Whitney U test was used to determine the significance of the difference between the indicated 
groups (***p < 0.0001; **p = 0.002; ns: not significant). (C) The experiments in B were repeated using a panel 
of 11 different YFV-derived/HLA class I tetramers. Mann Whitney U test was used to determine the significance 
of the difference between the indicated groups (***p < 0.0001; ns: not significant). (D) The activation status of 
YFV-specific CD8+ T cell was determined post vaccination for donor samples collected between day 12 and day 
22 after YFV vaccination. In the left-hand panel, PBMCs from primary vaccinated donors (“primary effectors”; 
n = 79) and from booster vaccinated donors (“secondary effectors”; n = 14) were stained ex vivo with a NS4B214-
222/HLA-A*02:01 tetramer. In the right-hand panel, PBMCs from primary vaccinated donors (“primary 
effectors”; n = 279) and from booster vaccinated donors (“secondary effectors”; n = 13) were stained ex vivo with 
tetramers relevant for their HLA haplotype. The activation status of these tetramer positive CD8+ T cells was 
determined as above. The median is indicated. A Mann Whitney U test was used to determine the significance 
of the difference between the groups (***p < 0.0001).
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(Fig. 2B, which shows naïve, primary effector, late memory and secondary effector responses ex vivo and after 
in vitro culture). Indeed, after in vitro culture, NS4B214-222-specific, HLA-A*02:01-restricted CD8+ T cells could 
be identified in 15 of the 16 late memory cultures, and in all primary and secondary effector cultures. However, 
we also observed clearly detectable, albeit much lower, NS4B214-222-specific responses in 15 of 18 naïve cultures 
suggesting that NS4B214-222-specific effector and memory responses observed after in vitro culture may not neces-
sarily be caused by vaccination. Noting that the HLA-A*02:01-restricted NS4B214-222 epitope is unusually strong 
and immunodominant, we again turned to the panel of 11 tetramers representing other immunodominant 
YF-17D-specific, HLA class I restricted CD8+ T cell epitopes (Fig. 2C). For the ex vivo responses, we found the 
same picture as with the HLA-A*02:01-restricted NS4B214-222 epitope: no naive responses, strong and frequent 
primary effector responses, absent late memory responses, and an even weaker and less frequent secondary effec-
tor responses (six detectable responses in 23 donors analysed). For the in vitro peptide stimulation responses, 
unlike for the NS4B214-222-specific, HLA-A*02:01-restricted CD8+ T cell responses, we did not observe any in 
vitro stimulation of cells from naïve individuals; something, which allowed us to interpret with greater certainty 
the in vitro experiments with CD8+ T cells obtained before or after a booster vaccination. In general, specific 
CD8+ T cells can only be in vitro expanded in vaccinated individuals. By this token, we found recruitable late 
memory YF-17D-specific T cells in the blood 10–30 years after vaccination. Strikingly, we observed strong ex vivo 
expansions of CD8+ T cells after primary vaccination; expansions that were much stronger than after booster 
vaccination.
Finally, we examined the degree of activation as determined by CD38+ and HLA-DR+ expression on 
YF-17D-specific, HLA class I tetramer-specific CD8+ T cells in primary and boosted donors. To this end we 
analysed blood samples, which had been donated between day 12 and day 22 after vaccination, where the activa-
tion level was at peak plateau level in primary vaccinated. In 66 of 79 HLA-A*02:01 positive and primary vacci-
nated donors examined, 85–100% of the NS4B214-222/HLA-A*02:01 tetramer positive CD8+ T cells were CD38+, 
whereas the corresponding figure for boosted donors tended to be less than 75% (Fig. 2D, left-hand panel). That 
this is a general phenomenon was further demonstrated when other YF-17D specific CD8+ T cells were examined 
(Fig. 2D, right-hand panel). Altogether, the CD8+ T cell response was significantly reduced following booster 
vaccination compared to primary vaccination, and in many cases, virtually absent.
CD38+, CD4+ T cell responses after primary and booster vaccination. Using the same approach 
as for the CD8 + T cells, we established a background frequency of activated CD4+, CD38+, HLA-DR+ T cells. 
It was found to be 0.35% (N = 159, SD = 0,166 with a 99% confidence interval of the mean from 0.32% to 0.39%. 
About 4% of the donors had apparent background frequency of 0.9% to almost 11% activated CD4+ T cells, and 
were removed as outliers. As for CD8+, CD38+, HLA-DR+ outliers, we speculate that these activated CD4+ outlier 
donors at the time of sampling might have had unnoticed infectious or inflammatory conditions.
We then examined the expression level and kinetics of the CD38 activation marker on CD4+ T cells during 
the acute immune response to YF-17D vaccination. Whereas up to 15–20% of CD8+ T cells expressed CD38 at 
the peak of the CD8+ T cell response, only up to 3–4% of CD4+ T cells expressed CD38 at the peak of the CD4+ 
T cell response (Fig. 3A). Similar to the CD8+ T cell response, the CD38 expression kinetics on CD4+ T cells rose 
rapidly around day 9 and peaked around day 14. The contraction phase started slightly earlier than for CD8+ T 
cells and reached a 0.5% level at day 22 (Fig. 3A). The expression levels of CD38 activation markers on CD4+ T 
cells after primary vaccination revealed a highly significant response (i.e. comparing naïve vs. primary effector 
samples, P < 0.0001), whereas no response was observed after booster vaccination (Fig. 3B, P < 0.17). Thus, like 
the CD8+ T cell response, the CD4+ T cell response was significantly reduced following booster vaccination com-
pared to primary vaccination, and in many cases virtually absent.
Functional T cell responses after primary and booster vaccination as measured by IFN-γ ELI 
Spot. To assess the functional cellular immune responses in primary and boosted donors and compare them 
quantitatively, we used PBMCs obtained from donors after vaccination and performed ex vivo IFN-γ ELI Spot 
analysis. Note, that this analysis compounds CD4+ and CD8+ T cell responses. For each of 100 primary and 18 
booster-vaccinated donors, we analysed a total of 30 pools each containing up to 30 overlapping peptides (15 
amino acids in length with an overlap of 11 amino acids) spanning the entire YF-17D proteome. Thus, summing 
up the number of IFN-γ producing cells per 106 cells obtained for all 30 peptide pools for a given donor gives a 
measure of the total anti-YF-17D T cell response of that donor (Fig. 3C). Albeit responses were detected in both 
primary and secondary effector T cells (i.e. after primary and booster vaccination, respectively), the responses 
detected in the primary effector samples were much higher than those obtained in the secondary effector samples, 
and this difference was highly significant.
Magnitude of the humoral/antibody response after primary and booster vaccina-
tion. Antibodies are the main effector mechanism in clearing Yellow Fever infection27, 35, 36. To examine the 
antibody responses in primary and booster vaccinated donors we used a plaque-reduction neutralizing test 
(PRNT) as a functional readout of the capacity of the vaccine to generate protective humoral immune responses. 
This PRNT assay was performed on pre- and post-vaccination sera from 28 primary and 28 booster vaccinated 
donors. Furthermore, memory samples from 11 of the primary vaccinated donors were collected approximately 
2 years after the primary vaccination. The result of the neutralization test is seen in Fig. 4A. None of the naïve 
donors, except one, had detectable antibodies. In contrast, all primary vaccinated donors generated neutralizing 
antibodies (a median titre of 1,280 (range from 160 to 20,480)). Two years after the primary vaccination, the 
neutralizing titre had fallen significantly in all 11 donors examined (a median titre of 160 (range from 80 to 640)). 
The neutralizing titres had fallen further prior to booster vaccination (a median titre of 20 (range from <2.5 to 
1,280)). Five of these 28 late memory stage donors, who had been primary vaccinated 26, 23, 11, 11, and 9 year 
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Figure 3. Activation of CD4+ T cells after primary and booster YF-17D vaccination. PBMCs were analysed 
by flow cytometry, and activated CD4+ T cells were defined as CD38+ HLA-DR+ CD4+ CD3+ T cells (see 
supplementary Figure S2, right-hand panel). (A) Frequencies of activated CD4+ T cells before and after YFV 
vaccination. Pre- (day 0) and post-vaccination (day 9 to 41) PBMCs from 209 primary YFV vaccinated donors 
were analysed. In the left-hand panel, pre-vaccination frequencies are plotted; in the right-hand panel, the 
post-vaccination frequencies are plotted according to the day the blood sample was collected. The median for 
each collection day is indicated. Mann Whitney U test was used to determine the significance of the difference 
between day 0 pre-vaccination, and the indicated day post vaccination (***p < 0.001; **p = 0.004; if nothing is 
given the sample size is too small). (B) The activation level of CD4+ T cells from primary and booster vaccinated 
donors before and after YFV vaccination. CD4+ T cell activation status was determined for PBMCs from 
primary vaccinated donors before (“naïve”; n = 147) and after (“primary effectors”; n = 178) vaccination and for 
PBMCs from booster vaccinated donors before (“late memory”; n = 29) and after (“secondary effectors”; n = 29) 
vaccination. The median is indicated. A Mann Whitney U test was used to determine the significance of the 
difference between the indicated groups (***p < 0.0001; **p = 0.001; *p = 0.0264; ns: not significant). (C) The 
total YFV specific CD4+ and CD8+ T cell responses in primary and booster vaccinated donors were analysed. 
PBMCs from primary vaccinated donors (“primary effector”; n = 100) and from booster-vaccinated donors 
(“secondary effector”; n = 18) were analysed ex vivo using IFN-γ specific ELISpot analysis using 30 peptide 
pools covering the entire YFV proteome. Only donors vaccinated 12–22 days prior to blood collection were 
included. For each donor, the total YFV specific T cell response was measured as the sum of IFN-γ specific cells 
(spot forming units, SFU per 106 PBMC). The median is indicated. Mann Whitney U test was used to determine 
the significance of the difference between the groups (***p < 0.0001).
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before, had titres below 10. The remaining 23 late memory donors had titres above 10 including donors that had 
been primary vaccinated 36 and 25 years ago, who had titre of 80 and 640, respectively. The booster vaccination 
led to a significant increase in neutralizing titre (a median of 1:160 (range from 1:80 to 1:1,280)); 21 of the 28 
booster vaccinated (75%) experienced a four-fold, or higher, increase in neutralizing titres, which conventionally 
is defined as being significant. Five experienced a non-significant two-fold titre increase, and the two remaining 
boosted donors had unaltered neutralizing titres of 2.5 and 10, respectively.
The effect of pre-existing antibodies on humoral immune responses following booster vacci-
nations of human vaccinees. Thus, whether judged by evaluation of CD8+ T cell, CD4+ T cell or humoral 
immune responses, the same conclusion was reached: that secondary effector responses against YF-17D vac-
cination are significantly lower than primary effector responses. We speculated that these reduced secondary 
effector responses could be caused by antibody-dependent neutralization and a diminished virus load leading to 
a reduced stimulation of the immune system35. To address this question, we examined whether high “pre-boost” 
titres correlated with reduced immune response to booster vaccination. Classically, >4-fold titre increase between 
paired samples is considered a strong indication of recent infection. Comparing “pre-boost” vs. “post-boost” 
neutralization titres, we observed >4-fold titre increase in 19 of 28 booster vaccinees. Examining whether a 
low “pre-boost” neutralizing titre correlated with >4-fold “post-boost” titre increase, we performed a “Receiver 
Operating Characteristics” (ROC) analysis where the true-positive rate is depicted against the false-positive rate 
at various thresholds of “pre-boost” titres. The area under this ROC curve, the “Area Under the Curve” (AUC), is 
0.74 (where an AUC of 1.00 defines a perfect relationship, and an AUC of 0.500 defines a random relationship) 
(Fig. 4B). This AUC is significant at the 5% level supporting the hypothesis that pre-existing antibodies inhibit the 
humoral immune response following a booster vaccination.
The effect of pre-existing antibodies on cellular immune responses following booster vaccina-
tions in an animal model. Unfortunately, we were unable to demonstrate a significant correlation between 
the presence of pre-existing antibody and reduced cellular immune responses following booster vaccination in 
humans. To perform this analysis in a better controlled system, we analysed CD8+ T cell responses induced 
by YFV vaccination in mice that had, or had not, been previously immunized with a recombinant Adenoviral 
vectored vaccine encoding the structural YF-17D proteins, core, membrane and envelope, denoted Ad-YF 
Figure 4. Antibody responses after primary and booster YF-17D vaccination. (A) Using a Plaque Reduction 
Neutralization Titre (PRNT) assay27, YFV specific neutralizing antibodies were assessed in sera from primary 
vaccinated donors (n = 28) before (“naïve”, n = 28), 12–22 days post-vaccination (“primary effector” n = 28), 
approximately 2 years post vaccination (“early memory”, n = 11); and from booster vaccinated donors before 
(“late memory”, n = 28) and after (“secondary effector”, n = 28) vaccination. The PRNT50 titre was defined as the 
reciprocal of the last serum dilution, which caused a 50% reduction in the number of plaques. The median is 
indicated. Mann Whitney U test was used to determine the significance of the difference between the indicated 
groups (***p < 0.0001; **p = 0.006). (B) A “Receiver Operating Characteristics” (ROC) analysis was performed 
to evaluate whether a high neutralizing antibody titre in the booster vaccinated donors prior to vaccination 
correlated with a reduced vaccination-induced titre increase (the latter classically defined as being >4-fold). 
True-positive rate is depicted against the false-positive rate at various thresholds of pre-booster vaccination 
titres. The area under this ROC curve (AUC) is 0.74 (p < 0.046).
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CME. This vector has been shown to induce neutralizing antibody titres detectable from day 7 to at least day 60 
post-vaccination. In mice, the whole attenuated YF-17D vaccine induces a CD8+ T cells response, which peaks at 
day 7 after infection and is specific for a dominant viral epitope present in the NS3 protein; this latter NS3-specific, 
CD8+ T cell response is not induced by the Ad-YF CME vaccine32. C57BL/6 mice, which had, or had not, been 
immunized with 2 * 107 pfu of the Ad-YF CME vaccine in the footpads (f.p.) 28 days earlier, were subcutaneously 
(s.c.) infected with 105 pfu of the YF-17D vaccine. Subsequently, the splenic CD8+ T cell responses were analysed 
by IFN-γ-specific intracellular cytokine staining (ICS) at day 6 and 8 after the YF-17D vaccination. A group of 
mice, which had only received the Ad-YF CME vaccination, was included for analysis of the memory CD8+ T 
cells response at the time of re-infection with the YF-17D vaccine. We found that NS3-specific CD8+ T cells 
could be detected in all the YF-17D vaccinated mice at day 8, but not day 6, after vaccination; strikingly, mice 
that had been immunized with the Ad-YF CME vaccine 28 days prior to YF-17D vaccination failed to generate 
NS3-specific CD8+ T cells (Fig. 5). These data support the notion that pre-existing YFV-specific antibodies can 
inhibit T cell responses induced by YF-17D vaccination.
Discussion
Until recently, the World Health Organization (WHO) has recommended that Yellow Fever “booster” vaccina-
tion of individuals at risk should be given ten years after past vaccination. In 2013, however, the WHO “Strategic 
Advisory Group of Experts on Immunization” (SAGE) removed this recommendation for healthy individuals 
since it considered a single dose of yellow fever vaccine sufficient to confer life-long protective immunity against 
the disease9, 37. The SAGE recommendation was adopted by the World Health Assembly in 2014, and entered 
into force legally (i.e. be removed from the International Health Regulations (IHR)) in June 2016. Similarly, the 
US Advisory Committee on Immunization Practices (ACIP) has voted that a single primary dose of yellow fever 
vaccine provides long-lasting protection and is adequate for most travelers38. It should be noted that the decision 
to discontinue to YFV booster vaccinations has been the subject of some discussion37, 39, 40.
Unfortunately, what constitutes sufficient protection against Yellow Fever virus infection is not fully under-
stood, and there is no accepted correlate of immune protection against YFV. Antibodies are generally considered 
to be the dominant protective mechanism of vaccines14, 15, 35, 36, 41 and have conventionally been viewed as the most 
appropriate correlate of immune protection. In this context, a single immunization generates neutralizing anti-
body titres, which may be detected in some vaccinees within 6 days, in 80–90% of vaccinees within 10 days, and 
in more than 99% within 28 days after vaccination1, 2, 9, 10, 13, 15, 41. Neutralizing antibody titres may persist for up to 
45 to 60 years after vaccination13–15, 42, 43. Here, we found an average neutralizing (PRNT) antibody titre of 1:1280 
(range 1:160 to 1:20,480) in primary vaccinees tested 9–40 days after vaccination (Fig. 4A). That neutralizing anti-
bodies is the dominant protective immune mechanism induced by YF-17D vaccination is corroborated by animal 
experiments involving either passive transfers of antibodies41 or genetically introduced immune deficiencies27.
While recognizing that neutralizing antibodies are associated with protection, SAGE also noted that “cellular 
immunity and innate immunity contribute to the initial immune response and sustaining the immune memory to 
yellow fever vaccination” and suggested “that a lack of detectable neutralizing antibodies may not mean a lack of 
protection against yellow fever viral infection among yellow fever vaccine recipients”. A priori, one would expect that 
many other arms of the immune system, innate as well as adaptive, are involved in the immune response induced 
by a primary YF-17D vaccination, and that all of these immune responses contribute to the superior efficiency of 
Figure 5. Pre-existing immunity to the YFV structural proteins (C,M,E) inhibits the CD8+ T cells response 
induced by YF-17D vaccination in mice. C57BL/6 (H-2b) mice were either untreated or vaccinated with 
an experimental adenoviral vectored vaccine, Ad-YF CME, directed against the structural proteins, core, 
membrane and envelope (C, M, E). Twenty-eight days later, all unvaccinated mice and half the vaccinated mice 
were s.c. immunized with the YF-17D vaccine, and the CD8+ T-cell response to the non-structural protein 
NS3 was determined. Following ex vivo peptide stimulation of splenocytes with NS3268-275, the number of 
CD44+IFN-γ+CD8+ T cells were determined 6 and 8 days post YFV infection using an intracellular cytokine 
staining (ICS); non-stimulated (no pep) cells served as controls. Symbols denote individual animals.
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the YF-17D vaccines16, 18, 20–23, 26, 29, 34, 44. Already Theiler observed that vaccinated animals were protected before 
neutralizing antibody titres could be detected43; something, which in hindsight could implicate additional pro-
tective immune mechanisms41. However, it is difficult to assess the effect of protective non-antibody mechanisms 
in the presence of a dominant antibody activity. Recently, we used genetically engineered mouse models to cir-
cumvent the obscuring effects of antibodies and address the effects of the remaining immune mechanism. In YFV 
vaccinated mice, we demonstrated an early (around day 5–7) and protective influx of specific CD8+ T cells, and 
CD8 T cell depletion resulted in increased organ viral load; results that to the best of our knowledge are the first 
demonstration of the protective effect against Yellow Fever virus of CD8+ T cells in isolation27.
Others have also suggested a role for CD8+ T cells. Miller et al. identified and used an activated CD8+ T cell 
phenotype, defined as being CD38+, HLA-DR+, KI-67+ and Bcl-2low, to analyse human CD8+ T cell activation 
and demonstrated that the human immune response to YF-17D vaccination involves a brisk expansion and acti-
vation of CD8+ T cells26. Here, using a simplified CD38+/HLA-DR+ phenotype to analyse the immune responses 
of 209 of 210 primary YF-17D vaccinees, we observed a rapid increase in the percentage of activated CD8+ T 
cells following YF-17D vaccination making this response detectable already around day 10–11, reaching a highly 
significantly peak plateau from around day 12 to 22 where an average of 5% (range 1 to 20%) of all CD8+ T cells 
were activated, following which they rapidly subsided during the fourth week of the response (Fig. 1A). Using the 
same simplified CD38+/ HLA-DR+ phenotype, we observed a similar, albeit less prominent, activation kinetics 
of CD4+ T cells (Fig. 3A). Implicitly, both CD8+ and CD4+ T cells must go through expansion since they a priori 
have emanated from T cell populations with very few YFV-specific CD8+ and CD4+ T cells.
A more direct analysis of CD8+ T cell activation and expansion, would be to use HLA class I tetramers to 
identify CD8+ T cells at the single cell level and then co-stain these for the CD38 and HLA-DR activations mark-
ers. Initially, we used an NS4B214-222/HLA-A*02:01 tetramer, which represents a particularly strong and immu-
nodominant YF-17D response. Our cohort of YF-17D vaccinees included 93 primary vaccinated HLA-A*02:01 
donors allowing us to address the kinetics of activation. From the earliest time point observed (9 days post 
vaccination) until day 16, virtually all NS4B214-222/HLA-A*02:01 specific CD8+ T cells had an activated phe-
notype. At that time, a contraction and de-activation phase started, where the fraction of activated, NS4B214-222/
HLA-A*02:01 specific CD8+ T cells began to drop reaching about 50% activated specific CD8+ T cells around 
day 22 and returning to low levels about day 30 (Fig. 1B and D). As shown here (and in unpublished results, A 
Stryhn), this epitope is recognized in every single YF-17D vaccinated, HLA-A*02:01 donor that we have exam-
ined; the frequencies of T cells responding ex vivo is unusually high (in some cases approaching 11%); and, in con-
trast to other CD8+ T cell responses we have examined, this specificity can be expanded in vitro in many naïve, 
HLA-A*02:01 positive, donors. The latter is in agreement with Blom et al.29, who observed that the NS4B214-222 
peptide could stimulate a small, but detectable, IFN-γ production in three of 9 naïve HLA-A*02:01 individuals. 
It has been suggested that these responses are the result of pre-existing, cross-reaction towards other pathogens45.
Thus, we were concerned that the unusually strong response of the NS4B214-222/HLA-A*02:01 specificity 
might not reflect primary response kinetics in general. To get a more representative picture of the activation 
kinetics of CD8+ T cells after YF-17D vaccination, we expanded the activation analysis of tetramer-specific cells 
to 11 additional YF-17D-derived epitopes, restricted to 11 HLA-I elements (see tetramer section of Materials 
and Methods). Compared to the NS4B214-222/HLA-A*02:01 epitope, these other epitopes are generally less dom-
inant, less frequent and do not show the same in vitro expansion and activation potential in naïve individuals. 
However, comparing the NS4B214-222/HLA-A*02:01 response with the 11 other responses, similar kinetics were 
observed. A priori, one should expect a stronger and more frequent CD8+ T cell response to clear an infection 
faster than a weaker and less frequent response, and that such a difference could be reflected in the deactivation 
kinetics, however, our results seems to indicated that this is not the case. Rather than being related to the resolu-
tion of the infection, the deactivation kinetics could be related to the gradual effector-to-memory transition of 
pre-programmed CD8+ T cells21, 26. In two donors, we consecutively sampled and analysed the expansion and 
activation of YF-17D-specific CD8+ T cells over a longer time period using relevant peptide-HLA-I tetramers 
(Fig. 1D). Early in the response and up to about day 20 day, all the tetramer-specific primary effector CD8+ T cells 
were of the activated phenotype. Thereafter, the population started to lose activation markers and diminish, how-
ever, even at day 450 and 960, a low, but detectable, number of tetramer-specific late memory CD8+ T cells could 
be observed. Thus, irrespective of which tetramer-specificities we monitored, the kinetics were in good agreement 
with the general activation kinetics observed in Fig. 1A, and with the kinetics reported by Akondy et al.21.
Strikingly, we found that the magnitudes of secondary (booster) responses induced by YF-17D were much 
reduced compared to primary responses. This reduction was observed for all parameters measured here: neu-
tralizing antibody titres; frequency of total activated CD4+ and CD8+ T cells, and of YFV-specific CD8+ T 
cells; and functional responses of YFV-specific CD4+ and CD8+ T cells. Wisseman et al. revaccinated eleven 
volunteers with YF-D17 about one year after primary vaccination and observed a reduced secondary neutralizing 
antibody response compared to the primary response46. In contrast, Reinhardt et al. revaccinated five volunteers 
more than 10 years after the primary YF-17D vaccination and observed a higher neutralizing antibody response 
in these revaccinated volunteers than in twelve primary vaccinated volunteers41. Revaccinating with the attenu-
ated measles vaccine, Christenson et al. showed that secondary antibody responses (as studied by ELISA, >300 
subjects) yielded significantly lower titres than primary vaccination, and that prior natural measles infection 
completely abrogated secondary antibody responses47. Other studies have compared the magnitude of the sec-
ondary humoral response to either the attenuated yellow fever (YF-17D) or measles vaccines as a function of 
the pre-existing (residual) antibody titres, and found that the higher residual antibody titre was, the lower the 
resulting secondary antibody response became14, 48, 49. Our analysis supports this inverse relationship between the 
magnitudes of the primary and secondary immune responses.
In animal models, several studies support the concept that pre-existing immunity, not only antibodies, but 
also T cells, may reduce the host response27, 32. Overall, our results are in agreement with the consensus view 
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expressed by Siegrist that “secondary responses to live attenuated viral vaccines are minimal, as pre-existing anti-
bodies mostly neutralize the vaccine load prior to its in vivo replication”35. In fact, one could argue that any kind 
of primary induced, acquired immune response, which could reduce the replication of a vaccine vector at the 
time of a revaccination challenge, would reduce the resulting secondary immune response50; and that any kind 
of secondary response could potentially be used to monitor this effect. In the context of the latter, Akondy et al. 
has recently demonstrated that the initial YF-17D load determines the magnitude of the CD8+ T cell response51; 
something that would suggest that the CD8+ T cell response could be used to monitor the effect of pre-existing 
immunity. Indeed, using a mouse model of Yellow Fever infection and a non-replicating adenoviral vectored 
vaccine, we here demonstrate that pre-existing immunity inhibit vaccine induced specific CD8+ T cell responses, 
and using human volunteers and the attenuated YF-17D vaccine, we further demonstrate that secondary CD8+ 
T cell responses are significantly reduced compared to primary responses. Besides the implications for YFV vac-
cination, our findings also raise a cautionary note regarding the practical use of YF-17D as a vaccine vector. 
Depending on the YF genes remaining after such genetic manipulations, efficient priming of immune responses 
directed against the heterologous components inserted into such a chimeric YF-17D-derived vaccine may be 
severely compromised by any pre-existing immunity directed against the YF-17D vector itself.
The use of YFV “booster” vaccinations was recently removed from the International Health Regulations. This 
was partly founded in the long-lived, probably life-long, immunity against Yellow Fever infection afforded by a 
single primary YFV immunization, partly in limited supplies of the YF-17D vaccine. Whilst it is true that high 
titres of neutralizing antibodies can be found decades after primary vaccination, this is not necessarily true for 
all primary vaccinated. About 25% of our volunteers, who were about to receive a booster vaccination 10 years, 
or more, after primary infection, had a PRNT titre of less than 1:5, and all, but one, responded with a significant 
increase in titres suggesting that the primary immune response was waning leading to a suboptimal immunity 
towards YFV thus allowing a booster dose of attenuated virus to infect its target cells and replicate. One could 
therefore argue that these individuals would benefit from a booster vaccination. However, in a situation with a 
limited supply of the vaccine and where new outbreaks occur regularly, one could also argue that immunizing 
naïve individuals at risk is a priority and a more efficient use of available vaccine supplies9.
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